Categories: CancerNews

Erasca to Present at the Bank of America Health Care Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca 
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

Staff

Recent Posts

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

45 minutes ago

Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship

The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…

4 hours ago

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…

4 hours ago

KLAS Report Shows Strong Early Results for TrustCommerce Cloud Payments

CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…

4 hours ago

BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter

MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…

4 hours ago

Truemed Closes $34 Million Series A To Unlock HSA/FSA Funds For Lifestyle Interventions

Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…

4 hours ago